Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats

Basit Öğe Kaydı
dc.contributor.authorSoner, Burak Cem
dc.contributor.authorAcikgoz, Eda
dc.contributor.authorInan, Salim Yalcin
dc.contributor.authorAyla, Sule
dc.contributor.authorSahin, Ayse Saide
dc.contributor.authorOktem, Gulperi
dc.date.accessioned2024-02-23T14:26:38Z
dc.date.available2024-02-23T14:26:38Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractParkinson's disease (PD) is the second most common neurodegenerative disorder, and the main cause of PD is still not known. Until now, no cure for Parkinson's disease is yet in sight. Caffeic acid phenethyl ester (CAPE) is a polyphenolic component of the propolis, which can be derived from honeybee hive propolis. We aimed to determine the effect of intrastriatal CAPE administration as a neuroprotective agent on 6-hydroxydopamine (6-OHDA)-induced PD model. Adult male Wistar rats weighing 280-320 g were used. The PD model was induced with unilateral intrastriatal 6-OHDA injection. Treatment groups received 20 mu mol/5 mu L/4 day and 80 mu mol/5 mu L/4 day CAPE 24 h after 6-OHDA injection. Eight days after 6-OHDA application, behavioral studies (adhesive tape removal test, open-field test, cylinder test, and apomorphine-induced asymmetric rotational behavior) were performed once more to compare the effects of CAPE on behavior tests. Striatal histological verifications, immunohistochemistry, and stereological quantitation were performed. Our results for the first time showed that, besides improving the motor performance, CAPE treatment also prevents 6-OHDA-induced loss of TH-positive neurons. From our results, CAPE may be a promising clinical agent in the treatment of PD.en_US
dc.description.sponsorshipScientific Research Projects Coordination Unit of the University of NE [151218009]en_US
dc.description.sponsorshipThis study was supported by grants from Scientific Research Projects Coordination Unit of the University of NE, project no. 151218009.en_US
dc.identifier.doi10.1155/2021/5553480
dc.identifier.issn2090-8083
dc.identifier.issn2042-0080
dc.identifier.pmid34512945en_US
dc.identifier.scopus2-s2.0-85115085149en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1155/2021/5553480
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14253
dc.identifier.volume2021en_US
dc.identifier.wosWOS:000695312000001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHindawi Ltden_US
dc.relation.ispartofParkinsons Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[Keyword Not Available]en_US
dc.titleNeuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu